Current Report Filing (8-k)
05 Avril 2019 - 11:28PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): April 5, 2019
INTELLIA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-37766
|
|
36-4785571
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
40 Erie Street, Suite 130
Cambridge, Massachusetts
|
|
02139
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area
code: (857) 285-6200
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if
the Form 8-K
filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act
(17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant
to
Rule 14d-2(b)
under the Exchange Act
(17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant
to
Rule 13e-4(c)
under the Exchange Act
(17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or
Rule 12b-2
of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01.
|
Entry into a Material Definitive Agreement.
|
On April 5, 2019, Intellia Therapeutics, Inc. (Intellia, the Company, or the Tenant), entered into a First Amendment
to Lease (the Lease Amendment) with MIT 130 Brookline Leasehold LLC (the Landlord). The Lease Amendment amends the Companys existing lease with the Landlord, dated as of October 21, 2014, as affected by a certain
letter agreement dated June 12, 2015 (collectively, the Lease), pursuant to which the Company leased approximately 15,169 rentable square feet of space in the building located at 130 Brookline Street, Cambridge, Massachusetts (the
Building).
The Lease Amendment provides for the term of the lease to be extended by five years from the original expiration date of January
31, 2020, as the Company duly exercised its option to extend the term of the lease for the period commencing February 1, 2020 and unless earlier terminated in accordance with the Lease, ending on January 31, 2025 (the Extension
Term). Base rent will be approximately $0.1 million per month for the first 12 months following the commencement of the Lease Amendment, with three percent annual increases thereafter through the Extension Term. As an inducement to the
Company entering into this Lease Amendment, the Landlord is providing a special tenant improvement allowance equal to approximately $0.2 million to be used by the Company solely for costs incurred by the Company for alterations to the premises
performed in accordance with certain articles of the Lease.
The foregoing description is a summary of certain terms of the Lease Amendment, and, by its
nature, is incomplete. It is qualified in its entirety by reference to the Lease Amendment which the Company expects to file as an exhibit to its Quarterly Report on Form
10-Q
for the quarter ended
March 31, 2019
.
2
SIGNATURE
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has caused this Report to be
signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Intellia Therapeutics, Inc.
|
|
|
|
|
Date: April 5, 2019
|
|
|
|
By:
|
|
/s/ John M. Leonard
|
|
|
|
|
Name:
|
|
John M. Leonard
|
|
|
|
|
Title:
|
|
Chief Executive Officer and President
|
3
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024